Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
about
Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trialEffectiveness of systematic screening for the detection of atrial fibrillationEffectiveness of systematic screening for the detection of atrial fibrillationPrediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort studySystematic screening for the detection of atrial fibrillationDirect Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and SimilaritiesAntithrombotic management of atrial fibrillation in the elderlyAtrial fibrillation: a review of recent studies with a focus on those from the duke clinical research instituteNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessAn evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Re-initiation of dabigatran and direct factor Xa antagonists after a major bleedAtrial fibrillation management in older heart failure patients: a complex clinical problemDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageUntreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment optionsStroke Prevention in Atrial Fibrillation: Focus on Latin AmericaUnder-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective AnalysisMedication assessment tool to detect care issues from routine data: a pilot study in primary care.MRI screening for chronic anticoagulation in atrial fibrillationImproving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial.Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort DataRationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa)Trends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995-2014.Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care EstimatorAn integrated epidemiological and neural net model of the warfarin effect in managed care patients.Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events.The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis.Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries.Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study.Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation?The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis.A standardized bleeding risk score aligns anticoagulation choices with current evidence.Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians.The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey.Stroke and bleeding risk in atrial fibrillation.Expanding use of new oral anticoagulants
P2860
Q21132512-DC36E8BD-98A9-4D18-94C9-B166AFF28B54Q24197923-3F790345-BD7E-4306-BCD4-F3E6CC809A0CQ24203942-D97922E3-1F5C-4F46-86B3-D36D21F2CADCQ24658646-7D76620B-391D-4E54-8359-050FACDB7954Q26471549-B8B46970-E8F2-4843-93A5-F755F9FF7CD7Q26787046-ACF5281E-4A0E-43EF-9BC4-CCA2304B6A85Q26827113-D750CD44-3A5E-422D-82BB-FA356CA90F69Q26851235-BB9D5085-1226-4BFE-8396-83D4263C231AQ26863548-6B717AA8-65CB-4FFA-B6E2-D8FDFB3BF329Q27027953-019E32F4-A310-4ECB-BD52-9EFD4126884FQ27341873-C134E1F1-D286-44BB-87DD-76B3C27942BDQ28067358-8A7C4B81-1D14-4C7F-B57A-F68C97CBD8CCQ28076170-FB4F93F8-9DBF-4966-904F-5BFBA40A8487Q28079930-B8F35133-B579-4A23-9DAF-A10BB01B7A9BQ28081837-9597834E-4235-4AFB-9AE6-BE90F9DA8A1EQ28359631-40CCCD69-F012-4C2C-A940-E3267B74BD67Q28553496-626F7BA2-EFFF-4F2F-83CD-16BEEDFC08B8Q30662415-42F71471-2C37-4642-AF74-B58E7C028F81Q30673203-2CA2A71C-FAF3-4642-A257-5AA899D47AEEQ30830699-53F33508-83DF-45C2-8249-627BDA204942Q30979197-C190D18A-0F71-4FEE-ABED-32C21DCD07E6Q31159143-FB40FFD8-83E4-4AEC-AB93-ED56E2263616Q33552973-7FEE3DF5-79CE-44BD-A739-554BA9DC9DACQ33565534-AAE4BF5D-D400-4DAB-89F7-93D18DC08810Q33572823-4AC4074B-D150-408C-B24F-E94D38092F75Q33719250-4586FEB8-6B51-47C1-9DC8-E1BCED5E4BD4Q33727817-1C4187FC-3E28-4C0E-82D6-43C0BDBE478CQ33731173-D2BD5842-A8DB-448B-8077-FEF888C9C240Q33786841-7F23C8C0-E9EF-4F9D-9171-3CB6B78B0C4EQ33828157-D89D12D6-90FE-462F-A822-5FB9BBA8753FQ33841770-A46B33B8-C14A-431C-8A31-C4FD3A8366FEQ33924253-9C6BA330-2702-4066-81EA-B9DBCC009F76Q33927278-F68DEE1C-2DB7-4C8D-824F-C4E268D73518Q33928951-3961C558-E723-46FC-A03D-54E96211EBA7Q33956677-AE42E544-7FF9-4F7B-96B0-51A4F95613CBQ33957383-606FE70B-A5A8-48A1-BBDB-AFC609D1732CQ34087971-2575B2DC-6A81-4967-BA75-38659E32544DQ34178980-3EE44106-6129-4331-9E3D-6AF2D7CF54C8Q34269633-99026BBB-0A85-4BAA-80F9-1F5770A5A2F8Q34312531-E36F6984-2D84-4F3A-8768-6B6B2F8C0D39
P2860
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@en
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@nl
type
label
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@en
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@nl
prefLabel
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@en
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@nl
P2093
P1476
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
@en
P2093
Isla M Ogilvie
Nick Newton
Sharon A Welner
Warren Cowell
P304
638-645.e4
P356
10.1016/J.AMJMED.2009.11.025
P407
P577
2010-07-01T00:00:00Z